Healthy Adult ParticipantsAsthma ExacerbationSafety and Efficacy
Investigational drug(s) / intervention(s)
RIG-101Placebo
RIG-101: Single, and repeat escalating intranasal administrations of RIG-101
Placebo: Single and repeat Intranasal administrations
Study summary
Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria:
Participants must meet all the following inclusion criteria to be eligible to participate in the trial.
* Participants must have a written informed consent obtained prior to any trial related procedure
* Male and female participants aged between 18 to 65 years inclusive, at the time of informed consent.
* Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead ECG and clinical laboratory assessments at the time of screening, as judged by the Investigator.
Additional Inclusion Criteria for Healthy Participants
\- Participants must have a pre-bronchodilator FEV1 ≥80% predicted (using GLI Global predicted values17) and an FEV1 / FVC ratio of \>70% absolute at screening.
Additional Inclusion Criteria for Participants with Asthma
* Participants must have a clinical diagnosis of asthma.
* Participants must have either a positive skin prick test with a wheal diameter of ≥3mm greater than control test at 15 minutes, and/or a blood eosinophil count of \> 200 cells / µL and/or a FeNO level of \> 25 ppb at screening.
* Participants must have a pre-bronchodilator FEV1 ≥65% predicted at screening
* Participants must be using SABA alone or inhaled corticosteroids (ICS) with SABA or ICS with formoterol as reliever therapy, AND/OR regular use of low to mid-dose ICS with or without LABA at a stable dose for at least 3 months prior to randomization to control their asthma.
Part B only
* Participants must have an ACQ-6 score of \> 0.75 at screening.
* Participants must have a history of asthma worsening in the previous 2 years, in response to a cold or respiratory infection, as confirmed by the participant.
* Participants must demonstrate seronegativity to RV-A16
Exclusion Criteria:
Exclusion Criteria for all Participants
* History or presence of any clinically relevant acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical trial, expose the participant to undue risk or interfere with the participants ability to successfully conduct the trial, as judged by the Investigator.
* Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the trial at time of screening.
* Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first administration of IMP and/or history of being hospitalized due to epistaxis on any previous occasion.
* Any nasal or sinus surgery within 3 months of the first administration of IMP
* Any signs of upper respiratory tract infection within 6 weeks of screening or prior to first administration of IMP
* Current or previous use of tobacco, nicotine products or e-cigarettes in the past 6 months prior to screening.
* Smoking history of \> 5 pack years.
Additional Exclusion Criteria for Participants with Asthma
* Any asthma exacerbation on their current asthma controller medication requiring oral/systemic corticosteroids within 8 weeks of randomization, or that resulted in overnight hospitalization requiring additional treatment for asthma within 3 months of randomization.
* Difficult-to-treat or severe asthma requiring the maintenance use of add-on biologic Type 2 targeted treatments including anti-Immunoglobulin E, anti-IL4 receptor, anti-IL5, anti-IL5 receptor, and anti-Thymic Stromal Lymphopoietin
* History of life-threatening asthma, defined as any asthma episode that required admission to a high-dependency or intensive therapy unit.
* Individuals with close contact to at risk patient groups
Primary outcome measure(s)
Adverse Events (AEs) and Serious Adverse Events (SAEs) — Day 1-35 All adverse events (AEs) and serious adverse events (SAEs) will be collected using standard regulatory AE/SAE monitoring procedures. Events will be assessed for severity and relationship to intranasal RIG-101 according to protocol-defined criteria. Data will be recorded from the signing of informed consent through the follow-up visit.
Systolic/Diastolic blood pressure — Day 0 - 35 Systolic/Diastolic blood pressure will be measured after participants rest in a supine position for ≥5 minutes.
Unit of Measure:
Change from baseline mmHg
Physical examinations — Day 0 -35 Physical examinations-general and system-specific (cardiovascular, respiratory, ENT, lymphatic, neurological, abdominal, musculoskeletal, dermatologic)-will be performed per protocol. Findings will be categorized as normal or abnormal, with clinical significance determined by the investigator.
Unit of Measure:
Incidence of clinically significant physical exam abnormalities
Nasal examinations — Day 0 - 35 Nasal examinations are performed to identify structural anomalies, inflammation, or other abnormalities in the anterior nares.
Unit of Measure:
Incidence of nasal exam abnormalities
Spirometry (FEV₁ and FVC) — Day 0-35 Spirometry (FEV₁ and FVC) will be conducted per ATS/ERS 2019 standards. Predicted values will use the GLI global dataset.
Unit of Measure:
Change from baseline in litres
Measurement Tool:
ATS/ERS-compliant spirometers
Triplicate 12-lead ECGs and single 12-lead ECGs — Day 0 - 35 Triplicate 12-lead ECGs and single 12-lead ECGs will be collected after ≥5 minutes of supine rest. Parameters include HR, PR interval, QRS duration, QT, and QTcF.
Unit of Measure:
Change from baseline in ECG parameters
Safety laboratory testing-haematology — Day 0 - 35 Safety laboratory testing-haematology, will be assessed per protocol and judged for clinical significance.
Unit of Measure:
Change in parameters of haematology laboratory values assessed using local lab reference ranges
Safety laboratory testing-Serum Chemistry — Day 0- 35 Safety laboratory testing-Serum chemistry, will be assessed per protocol and judged for clinical significance.
Unit of Measure:
Change in parameters of Serum chemistry laboratory values assessed using local lab reference ranges
Safety laboratory testing-Coagulation — Day 0 -35 Safety laboratory testing-Coagulation will be assessed per protocol and judged for clinical significance.
Unit of Measure:
Change in parameters of Coagulation laboratory values assessed using local lab reference ranges
Lower respiratory tract symptom score assessments — Day -7 to 35 Participants complete twice-daily LRSS assessments for 35 days. The primary endpoint is the total symptom burden expressed as area under the curve (AUC) for LRSS from baseline through Day 35.
Unit of Measure:
AUC (LRSS × days)
Measurement Tool:
Twice-daily electronic diary (eDiary) symptom scoring system
AUC of Lower respiratory tract symptom score — Day -7 to 35 AUC of LRSS where the lower respiratory symptoms are measured for 35 days by twice-daily date and time stamped eDiary collection
Vital Signs - heart rate — Day 0 - 35 Heart rate will be measured after participants rest in a supine position for ≥5 minutes.
Unit of Measure: Change from baseline BPM
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.